Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndromeAndrew Chase, Nicholas C.P. Cross|Haematologica|2012Cited by 71
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangementsAndrew Chase, Nicholas C.P. Cross|Haematologica|2012Cited by 35